[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease

  • Shizuo Hatashita
  • Hidetomo Yamasaki
  • Yutaka Suzuki
  • Kumiko Tanaka
  • Daichi Wakebe
  • Hideki Hayakawa
Original Article

Abstract

Purpose

The aim was to identify the amyloid beta (Aβ) deposition by positron emission tomography (PET) imaging with the 18F-labeled Pittsburgh compound B (PIB) derivative [18F]flutemetamol (FMM) across a spectrum of Alzheimer’s disease (AD) and to compare Aβ deposition between [18F]FMM and [11C]PIB PET imaging.

Methods

The study included 36 patients with AD, 68 subjects with mild cognitive impairment (MCI), 41 older healthy controls (HC) (aged ≥56), 11 young HC (aged ≤45), and 10 transitional HC (aged 46–55). All 166 subjects underwent 30-min static [18F]FMM PET 85 min after injection, 60-min dynamic [11C]PIB PET, and cognitive testing. [18F]FMM scans were assessed visually, and standardized uptake value ratios (SUVR) were defined quantitatively in regions of interest identified on coregistered MRI (cerebellar cortex as a reference region). The PIB distribution volume ratios (DVR) were determined in the same regions.

Results

Of 36 AD patients, 35 had positive scans, while 36 of 41 older HC subjects had negative scans. [18F]FMM scans had a sensitivity of 97.2 % and specificity of 85.3 % in distinguishing AD patients from older HC subjects, and a specificity of 100 % for young and transitional HC subjects. The [11C]PIB scan had the same results. Interreader agreement was excellent (kappa score = 0.81). The cortical FMM SUVR in AD patients was significantly greater than in older HC subjects (1.76 ± 0.23 vs 1.30 ± 0.26, p < 0.01). Of the MCI patients, 68 had a bimodal distribution of SUVR, and 29 of them (42.6 %) had positive scans. Cortical FMM SUVR values were strongly correlated with PIB DVR (r = 0.94, n = 145, p < 0.001).

Conclusion

[18F]FMM PET imaging detects Aβ deposition in patients along the continuum from normal cognitive status to dementia of AD and discriminates AD patients from HC subjects, similar to [11C]PIB PET.

Keywords

Alzheimer’s disease Amyloid imaging PET Amyloid beta (Aβ) 

References

  1. 1.
    McKhann G, Drachman DA, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 1993;7:152–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:257–62.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’ disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in human using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 2008;131:1630–45.PubMedCrossRefGoogle Scholar
  8. 8.
    Hatashita S, Yamasaki H. Clinically different stages of Alzheimer’s disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 2010;21:995–1003.PubMedGoogle Scholar
  9. 9.
    Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Brthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424–35.CrossRefGoogle Scholar
  11. 11.
    Cselenyi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 2012;53:415–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Neilssen N, Van Laere K, Thurfiell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251–9.CrossRefGoogle Scholar
  13. 13.
    Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment A phase 2 trial. Ann Neurol 2010;68:319–29.PubMedCrossRefGoogle Scholar
  14. 14.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Wechsler DA. Wechsler memory scale-revised. New York: Psychological Corporation; 1987.Google Scholar
  17. 17.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s Association. Alzheimers Dement 2011;7:263–9.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Albert MS, DeKosky ST, Diskson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–9.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Smith A, Buckley C, Sherwin P, Heurling K, Ikonomovic M, Mathis C, et al. Evaluation of the histopathology burden underlying [18F]flutemetamol PET imaging (abstract). Human Amyloid Imaging 2013;7:32.Google Scholar
  20. 20.
    Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68(11):1404–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013;8(6):e66877. doi:10.1371/journal.pone.0066877.
  23. 23.
    Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012;39:983–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Shizuo Hatashita
    • 1
  • Hidetomo Yamasaki
    • 1
  • Yutaka Suzuki
    • 2
  • Kumiko Tanaka
    • 3
  • Daichi Wakebe
    • 2
  • Hideki Hayakawa
    • 2
  1. 1.Neurology, PET CenterShonan-Atsugi HospitalAtsugiJapan
  2. 2.Radiology, PET CenterShonan-Atsugi HospitalAtsugiJapan
  3. 3.Pharmacology, PET CenterShonan-Atsugi HospitalAtsugiJapan

Personalised recommendations